In patients with SSc-ILD, several biomarkers (e.g. anti-topoisomerase 1, C-reactive protein (CRP), Interferon gamma induced protein 10 (IP-10, CXCL10) Interleuken-23 (IL-23), and Interleukin-6 (IL-6)) have been suggested to be linked with disease progression in both dcSSc and lcSSc (9–12). This evidence concerns the gene IL6 and systemic sclerosis.